THAR
Price:
$2.47
Market Cap:
$86.56M
Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics. The company was formerly known as Hillstream BioPharma, Inc. and changed...[Read more]
Industry
Biotechnology
IPO Date
2022-01-12
Stock Exchange
NASDAQ
Ticker
THAR
According to Tharimmune, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.67. This represents a change of 66.33% compared to the average of -0.40 of the last 4 quarters.
The mean historical PE Ratio of Tharimmune, Inc. over the last ten years is -9.51. The current -0.67 PE Ratio has changed 604.81% with respect to the historical average. Over the past ten years (40 quarters), THAR's PE Ratio was at its highest in in the December 2021 quarter at 4.03. The PE Ratio was at its lowest in in the June 2020 quarter at -37.10.
Average
-9.51
Median
-7.67
Minimum
-23.49
Maximum
-0.07
Discovering the peaks and valleys of Tharimmune, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 202.37%
Maximum Annual PE Ratio = -0.07
Minimum Annual Increase = -97.10%
Minimum Annual PE Ratio = -23.49
| Year | PE Ratio | Change |
|---|---|---|
| 2024 | -0.22 | 202.37% |
| 2023 | -0.07 | -86.30% |
| 2022 | -0.52 | -97.10% |
| 2021 | -17.92 | 20.93% |
| 2020 | -14.82 | -36.90% |
The current PE Ratio of Tharimmune, Inc. (THAR) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-0.27
5-year avg
-6.71
10-year avg
-9.51
Tharimmune, Inc.’s PE Ratio is greater than BioLineRx Ltd. (-1.69), less than GeoVax Labs, Inc. (-0.31), less than Adlai Nortye Ltd. (-0.25), less than Lunai Bioworks Inc. (-0.12), greater than SeaStar Medical Holding Corporation (-0.69), less than Adaptimmune Therapeutics plc (-0.08), greater than Ainos, Inc. (-0.76), less than Apollomics, Inc. (-0.30), less than Aditxt, Inc. (-0.00), less than Moleculin Biotech, Inc. (-0.28),
| Company | PE Ratio | Market cap |
|---|---|---|
| -1.69 | $14.17M | |
| -0.31 | $9.73M | |
| -0.25 | $37.48M | |
| -0.12 | $23.14M | |
| -0.69 | $10.01M | |
| -0.08 | $75.16M | |
| -0.76 | $12.03M | |
| -0.30 | $16.27M | |
| -0.00 | $62.61K | |
| -0.28 | $9.32M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Tharimmune, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Tharimmune, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Tharimmune, Inc.'s PE Ratio?
How is the PE Ratio calculated for Tharimmune, Inc. (THAR)?
What is the highest PE Ratio for Tharimmune, Inc. (THAR)?
What is the 3-year average PE Ratio for Tharimmune, Inc. (THAR)?
What is the 5-year average PE Ratio for Tharimmune, Inc. (THAR)?
How does the current PE Ratio for Tharimmune, Inc. (THAR) compare to its historical average?